An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 10, 2011, Pages 1491-1497

  Di Lorenzo, Giuseppe ^a   Casciano, Roman ^b   Malangone, Elisabetta ^b   Buonerba, Carlo ^a   Sherman, Steven ^b   Willet, Jacob ^b   Wang, Xufang ^c   Liu, Zhimei ^c   De Placido, Sabino ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Analytica International   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

biostatistics; everolimus; overall survival; renal cancer; sorafenib

Indexed keywords

ALPHA INTERFERON; ASCORBIC ACID; AXITINIB; BEVACIZUMAB; EVEROLIMUS; INTERFERON; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POPULATION RISK; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PYRIDINES; PYRROLES; SIROLIMUS; SURVIVAL; TREATMENT OUTCOME;

EID: 79958734431     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.587119     Document Type: Article

References (26)

1. How Does SUTENT-Work? [Website]; Available from: http://www.sutent.com/ RCC/rcc-how-sutent-works.aspx.[Cited 13 July 2010]
2. Nexavar Full Prescribing Information. 2009 [Cited 13 July 2010]
3. Di Lorenzo G, Autorino R, Sternberg CN. Metastatic renal cell carcinoma: recent advances in the targeted therapy era. Eur Urol 2009;56(6):959-71
4. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;12(2):125-34 (Pubitemid 46089673)
5. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24 (Pubitemid 46089672)
6. Novartis Pharmaceuticals Corp. Afinitor (sorafenib) Prescribing Information; 2009
7. Kay A, Motzer RJ, Figlin RA. Updated data from a phase III randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell carcinoma (mRCC) [abstract 278]. Presented at ASCO Genitourinary Cancers Symposium; 2009
8. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449-56
9. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116(18):4256-65
10. Gu XS, Rosenbaum PR. Comparison of mutlivariate matching methods: structures, distances, and algorithms. J Comput Graph Stat 1993;2:405-20
11. Casciano R, Malangone E, Sherman S, et al. An indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory mRCC patients [abstract 4611]. J Clin Oncol 2010;28:15s
12. Di Lorenzo G, Carteni G, Autorino R, et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 2009;27(27):4469-74
13. Beck SD, Patel MI, Snyder ME, et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol 2004;11(1):71-7
14. Ronnen EA, Kondagunta GV, Ishill N, et al. Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer 2006;107(11):2617-21 (Pubitemid 44845616)
15. Motzer RJ, Bacik J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002;20(9):2376-81 (Pubitemid 34441667)
16. Heng DYC. Bukowski, RM. Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinoma. Oncol Rev 2007;1(3):170-6
17. Spruance SL, Reid JE, Grace M, et al. Hazard ratio in clinical trials. Antimicrob Agents Chemother 2004;48(8):2787-92 (Pubitemid 38989137)
18. Ljungberg B, Hanbury DC, Kuczyk MA, et al. Renal cell carcinoma guideline. Eur Urol 2007;51(6):1502-10 (Pubitemid 46634775)
19. De Reijke TM, Bellmunt J, van Poppel H, et al. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer 2009;45(5):765-73
20. Bellmunt J, Calvo E, Castellano D, et al. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer. Cancer Chemother Pharmacol 2009;63(Suppl 1):S1-13
21. Nathan P, Wagstaff J, Porfiri E, et al. UK guidelines for the systemic treatment of renal cell carcinoma. Br J Hosp Med (Lond) 2009;70(5):284-6
22. NCCN. NCCN Clinical Practice Guidelines in Oncology. Kidney Cancer. V.2.2010. NCCN 2009
23. Gartlehner G, Moore CG. Direct versus indirect comparisons: a summary of the evidence. Int J Technol Assess Health Care 2008;24(2):170-7 (Pubitemid 351519516)
24. Signorovitch J. Robust comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics 2010;28(10):935-45
25. Song F, Harvey I, Lilford R. Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. J Clin Epidemiol 2008;61(5):455-63 (Pubitemid 351446184)
26. Motzer RJ, Mazumbar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17(8):2530-40 (Pubitemid 29368255)